A review published by Akshitha Thatiparthi et al. suggests IL-17 inhibitors or IL-23 inhibitors should be used in patients with LTBI, with ustekinumab or TNF-α inhibitors after TB prophylaxis [39]. This evidence concerns the gene TNF and tuberculosis.